Technological advances in iPS drug discovery and regenerative medicine, and rising expectations for practical applications
First written in FY2024-H1. 1 of 2 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「In addition to our own activities, announcements have been made regarding the discovery of iPS drug discovery candidates, technologies for producing organs and other structures using iPS cells, mass-culture technologies and expansions of cell-culture facilities. Expectations for technological progress and practical application in the iPS drug discovery and regenerative medicine businesses are therefore increasing.」
The company reiterates that announcements by other companies and organizations regarding iPS drug discovery candidates, production and mass-culture technologies and facility expansions are raising expectations for technological progress and practical application. - FY2024-H1First statedAnnual report
「In addition to our own activities, announcements have been made regarding the discovery of iPS drug discovery candidates, technologies for producing organs and other structures using iPS cells, and mass-culture technologies. Expectations for technological progress and practical application in the iPS drug discovery and regenerative medicine businesses are therefore increasing.」
The company explains that announcements by other companies and organizations regarding iPS drug discovery candidates, organ-production and mass-culture technologies are raising expectations for technological progress and practical application in both businesses.